IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
CEO: Ari Bousbib. Company website
IQVIA Holdings Inc. (IQV) trades at $266.42, down 1.12% on the day, as of Sep 20, 2026 13:47 UTC.
IQVIA Holdings Inc. has a market capitalisation of $43.85B, calculated from the live IQV share price and shares outstanding.
IQV trades at a trailing P/E of 33.05, from earnings per share of $8.06 over the last twelve months.
IQVIA Holdings Inc. generated revenue of $16.98B over the trailing twelve months, which puts the stock at 2.58 times sales.
IQV has traded between $154.50 and $273.88 over the past 52 weeks, and the last price is 2.7% below that high.
Yes. IQVIA Holdings Inc. keeps 8.10% of revenue as net income over the trailing twelve months.
Wall Street analysts rate IQV Buy, with an average price target of $237.38, 10.9% below the current price.
IQVIA Holdings Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Ari Bousbib is the chief executive of IQVIA Holdings Inc., which employs 94,000 people.
QFI Terminal shows IQV with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open IQV in Terminal See plans